[Federal Register Volume 79, Number 227 (Tuesday, November 25, 2014)]
[Notices]
[Pages 70195-70196]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-27820]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by writing to 
the indicated licensing contact at the Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to 
receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

T-cell Chimeric Receptors of TSLPR for Diagnosis and Immunotherapy of 
Cancer

    Description of Technology: T-cell-based immunotherapies allow a 
patient's immune system to concentrate its efforts and destroy cancer 
cells. In the present technology, the researchers at the National 
Cancer Institute have developed chimeric antigen receptors (or CARs), 
which encode an antigen binding domain specific for thymic stromal 
lymphopoietin receptor (TSLPR) and a T-cell signaling domain. TSLPR is 
over-expressed on the surface of approximately 10% of adult and 
pediatric B-cell precursor acute lymphoblastic leukemias (BCP-ALL).
    Available for licensing is the above-reference CAR technology as 
well as methods for diagnosing and treating cancer using these CARs.
    Potential Commercial Applications:

<bullet> Immunotherapy against cancer, especially leukemia
<bullet> Immunotoxins

    Competitive Advantages: CAR receptors are specific for TSLPR.
    Development Stage:

<bullet> In vitro data available
<bullet> In vivo data available (animal)
<bullet> Prototype

    Inventors: Terry Fry and Haiying Qin (NCI).
    Publication: Qin H, et al. Pre-clinical development of a novel 
chimerical antigen receptor targeting high-risk pediatric ALL over-
expressing Tslpr. Blood 2013 Nov 15;122(21):2665.
    Intellectual Property:

<bullet> HHS Reference No. E-008-2014/0--US Provisional Application No. 
61/912,948 filed 06 Dec 2013
<bullet> HHS Reference No. E-008-2014/1--US Provisional Application No. 
61/991,697 filed 12 May 2014
<bullet> HHS Reference No. E-008-2014/2--PCT Application No. PCT/
US2014/063096 filed 30 Oct 2014

    Licensing Contact: Patrick McCue, Ph.D.; 301-435-5560; 
<a href="/cdn-cgi/l/email-protection#98f5fbfbedfde8f9ecd8f5f9f1f4b6f6f1f0b6fff7ee"><span class="__cf_email__" data-cfemail="5c313f3f29392c3d281c313d353072323534723b332a">[email protected]</span></a>

Novel Bridged Bicyclic Thiazepinone Compounds

    Description of Technology: The invention is directed to small 
molecules containing a novel, bridged, bicyclic thiazepinone 
pharmacophore. Invention compounds inhibit the Nav1.7 sodium channel. 
Additionally, invention compounds bind the human norepinephrine 
transporter (NET), with selectivity over the serotonin transporter 
(SERT) and dopamine transporter (DAT).
    Invention compounds could be used to treat neuropathic pain 
associated with diabetes and fibromyalgia, Attention Deficit 
Hyperactivity Disorder (ADHD), urinary incontinence, depression, 
anxiety, and other mood disorders.
    Invention compounds can be conjugated with fluorescent or 
radioactive tags, and used to probe the structure and activity of the 
Nav1.7 sodium channel and NET.
    Potential Commercial Applications:

<bullet> Therapeutic
<bullet> Chemical probe

    Competitive Advantages:

<bullet> Small molecule compounds made using facile synthesis scheme
<bullet> Inhibition of Nav1.7 sodium channel
<bullet> NET inhibition with selectivity over other transporters

    Development Stage:

<bullet> Early-stage
<bullet> In vitro data available
    Inventors: Hans F. Luecke (NIDDK), Michael T. Scerba (NIDDK), 
Dongwook Kang (Daegu Catholic University).

Intellectual Property: HHS Reference No. E-224-2012/0--
<bullet> US Application No. 61/876,262 filed 09 Sept 2013
<bullet> PCT Application No. PCT/US2014/054660 filed 09 Sept 2014

    Licensing Contact: Lauren Nguyen-Antczak, Ph.D., J.D.; 301-435-
4074; <a href="/cdn-cgi/l/email-protection#721c15070b171c131c06110813191e13321f131b1e5c1c1b1a5c151d04"><span class="__cf_email__" data-cfemail="2a444d5f534f444b445e49504b41464b6a474b434604444342044d455c">[email protected]</span></a>.
    Collaborative Research Opportunity: The National Institute of 
Diabetes and Digestive and Kidney Diseases is seeking statements of 
capability or interest from parties interested in collaborative 
research to further develop, evaluate or commercialize use of bridged 
bicyclic thiazepinones. For collaboration opportunities, please contact 
Marguerite J. Miller, M.B.A. at <a href="/cdn-cgi/l/email-protection#b0ddd1c2d7c5d5c2d9c4d59eddd9dcdcd5c2f0ded9d89ed7dfc6"><span class="__cf_email__" data-cfemail="107d7162776575627964753e7d797c7c7562507e79783e777f66">[email protected]</span></a> or 301-496-
9003.


[[Page 70196]]


    Dated: November 18, 2014.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2014-27820 Filed 11-24-14; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>